|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_ocn951076082 |
| 003 |
OCoLC |
| 005 |
20231120112112.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
160603s2016 enk o 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d N$T
|d EBLCP
|d OPELS
|d N$T
|d OCLCF
|d YDXCP
|d OCLCQ
|d NRC
|d OCLCQ
|d U3W
|d D6H
|d NLE
|d UKMGB
|d OCLCQ
|d S2H
|d OCLCO
|d LVT
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB6I0970
|2 bnb
|
| 016 |
7 |
|
|a 017884839
|2 Uk
|
| 019 |
|
|
|a 951032507
|a 1229754919
|
| 020 |
|
|
|a 0128021640
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128021644
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128021736
|
| 020 |
|
|
|z 012802173X
|
| 035 |
|
|
|a (OCoLC)951076082
|z (OCoLC)951032507
|z (OCoLC)1229754919
|
| 050 |
|
4 |
|a RC523
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.8/31061
|2 23
|
| 245 |
0 |
0 |
|a Developing therapeutics for Alzheimer's disease :
|b progress and challenges /
|c edited by Michael S. Wolfe.
|
| 260 |
|
|
|a London :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (678)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a 1. The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer's Disease; 2. The Genetic Basis of Alzheimer's Disease; 3. B-Secretase Inhibition; 4. Y-Secretase Inhibitors: from Chemical Probes to Drug Development; 5. Therapeutic Targeting of AB42; 6. Modulators of Amyloid B-Protein (AB) Self-Assembly; 7. Anti-Amyloid-B Immunotherapy for Alzheimer's Disease; 8. Targeting AB Receptors to Modify Alzheimer's Disease Progression; 9. Blood-Brain Barrier Transport of Alzheimer's Amyloid B-Peptide; 10. Alzheimer's Disease Therapeutics Targeting Apolipoprotein E; 11. Microtubule Stabilization; 12. Tau Phosphorylation as a Therapeutic Target in Alzheimer's Disease; 13. Stimulation of Tau Degradation; 14. Passive Immunotherapy for Tau Pathology; 15. Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease; 16. Neuroprotective Strategies for Alzheimer's Disease Prevention and Therapy; 17. Symptomatic Cognitive Enhancing Agents; 18. Tackling Alzheimer's Disease by Targeting Oxidative Stress and Mitochondria; 19. Preclinical and Clinical Issues in Alzheimer Drug Development; 20. Molecular Imaging in Alzheimer Clinical Trials; 21. Fluid Biomarkers and Diagnostics; 22. Non-Pharmacologic Activity Interventions to Prevent Alzheimer's Disease; 23. Prospects and Challenges for Alzheimer Therapeutics
|
| 650 |
|
0 |
|a Alzheimer's disease
|x Chemotherapy.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
6 |
|a Maladie d'Alzheimer
|x Chimioth�erapie.
|0 (CaQQLa)201-0330307
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Alzheimer's disease
|x Chemotherapy
|2 fast
|0 (OCoLC)fst00806536
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 700 |
1 |
|
|a Wolfe, Michael S.
|
| 776 |
0 |
8 |
|i Print version:
|t Developing therapeutics for Alzheimer's disease.
|d London : Academic Press is an imprint of Elsevier, 2016
|z 012802173X
|z 9780128021736
|w (OCoLC)938382920
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128021736
|z Texto completo
|
